• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A natural history comparison of SOD1-mutant patients with amyotrophic lateral sclerosis between Chinese and German populations.

作者信息

Tang Lu, Dorst Johannes, Chen Lu, Liu Xiaolu, Ma Yan, Günther Kornelia, Michels Sebastian, Müller Kathrin, Freischmidt Axel, Weishaupt Jochen H, Fan Dongsheng, Ludolph Albert C

机构信息

Department of Neurology, Peking University Third Hospital, Beijing, 100191, China.

Beijing Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Peking University Third Hospital, Beijing, 100191, China.

出版信息

Transl Neurodegener. 2021 Oct 28;10(1):42. doi: 10.1186/s40035-021-00266-x.

DOI:10.1186/s40035-021-00266-x
PMID:34711284
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8555265/
Abstract
摘要

相似文献

1
A natural history comparison of SOD1-mutant patients with amyotrophic lateral sclerosis between Chinese and German populations.中国和德国人群中携带超氧化物歧化酶1（SOD1）基因突变的肌萎缩侧索硬化症患者的自然史比较
Transl Neurodegener. 2021 Oct 28;10(1):42. doi: 10.1186/s40035-021-00266-x.
2
Slow progression of amyotrophic lateral sclerosis in a Chinese patient carrying SOD1 p.S135T mutation.一名携带SOD1 p.S135T突变的中国患者肌萎缩侧索硬化症进展缓慢。
Amyotroph Lateral Scler Frontotemporal Degener. 2022 Feb;23(1-2):143-145. doi: 10.1080/21678421.2021.1912771. Epub 2021 Apr 16.
3
Amyotrophic lateral sclerosis with long lasting disease course and SOD1 and TARDBP mutations: Report of two cases and overview of the literature.病程持久且伴有超氧化物歧化酶1（SOD1）和反式激活反应DNA结合蛋白（TARDBP）突变的肌萎缩侧索硬化症：两例报告及文献综述
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):137-139. doi: 10.1080/21678421.2016.1212896. Epub 2016 Aug 5.
4
New mutation in the SOD1 (copper/zinc superoxide dismutase-1) gene in a Chinese amyotrophic lateral sclerosis (ALS) patient.在中国肌萎缩侧索硬化症（ALS）患者中 SOD1（铜/锌超氧化物歧化酶-1）基因的新突变。
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):635-7. doi: 10.3109/21678421.2013.817589. Epub 2013 Jul 29.
5
Amyotrophic lateral sclerosis due to a SOD1 mutation and X-linked recessive bulbospinal neuronopathy in a single family.一个家族中由超氧化物歧化酶1（SOD1）突变引起的肌萎缩侧索硬化症和X连锁隐性延髓脊髓神经元病。
Acta Neurol Belg. 2019 Dec;119(4):641-643. doi: 10.1007/s13760-019-01124-4. Epub 2019 Mar 16.
6
A novel nonsense mutation (p.Asn140Ter) in a sporadic amyotrophic lateral sclerosis case with rapid progression.一个散发型肌萎缩侧索硬化症快速进展病例中出现的新型无义突变（p.Asn140Ter）。
Amyotroph Lateral Scler Frontotemporal Degener. 2021 Nov;22(7-8):583-584. doi: 10.1080/21678421.2021.1871629. Epub 2021 Jan 15.
7
Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis.大规模 SOD1 突变筛查为肌萎缩侧索硬化症的遗传异质性提供了证据。
J Neurol Neurosurg Psychiatry. 2010 May;81(5):562-6. doi: 10.1136/jnnp.2009.181453. Epub 2009 Dec 3.
8
The epidemiology of CuZn-SOD mutations in Germany: a study of 217 families.德国 CuZn-SOD 突变的流行病学：217 个家族的研究。
J Neurol. 2010 Aug;257(8):1298-302. doi: 10.1007/s00415-010-5512-9. Epub 2010 Mar 23.
9
D90A-SOD1 ALS mimicking monoclonal gammopathy-associated ALS.D90A-SOD1 肌萎缩侧索硬化症模拟单克隆丙种球蛋白病相关的肌萎缩侧索硬化症。
Amyotroph Lateral Scler. 2012 May;13(3):326-7. doi: 10.3109/17482968.2012.656312. Epub 2012 Mar 13.
10
Familial ALS in Germany: origin of the R115G SOD1 mutation by a founder effect.德国的家族性肌萎缩侧索硬化症：R115G SOD1突变源于奠基者效应。
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1186-8. doi: 10.1136/jnnp.2003.028324.

引用本文的文献

1
The role of rs671 polymorphism and C-reactive protein in the phenotypes of male ALS patients.rs671基因多态性与C反应蛋白在男性肌萎缩侧索硬化症患者表型中的作用
Front Neurosci. 2024 Sep 3;18:1397991. doi: 10.3389/fnins.2024.1397991. eCollection 2024.
2
Clinical characterization of common pathogenic variants of SOD1-ALS in Germany.德国超氧化物歧化酶1型肌萎缩侧索硬化常见致病变异的临床特征
J Neurol. 2024 Oct;271(10):6667-6679. doi: 10.1007/s00415-024-12564-1. Epub 2024 Aug 14.
3
Disease survival and progression in TARDBP ALS patients from Sardinia, Italy.意大利撒丁岛 TARDBP ALS 患者的疾病生存和进展。
J Neurol. 2024 Feb;271(2):929-934. doi: 10.1007/s00415-023-12037-x. Epub 2023 Oct 19.
4
Another mutation in the gene: the first Turkish patient with -His47Arg, a case report.该基因的另一种突变：首例携带-His47Arg的土耳其患者，病例报告。
Front Genet. 2023 Aug 25;14:1208673. doi: 10.3389/fgene.2023.1208673. eCollection 2023.
5
Predictors for progression in amyotrophic lateral sclerosis associated to SOD1 mutation: insight from two population-based registries.SOD1 突变相关性肌萎缩侧索硬化症进展的预测因素：来自两个基于人群的登记处的见解。
J Neurol. 2023 Dec;270(12):6081-6092. doi: 10.1007/s00415-023-11963-0. Epub 2023 Sep 5.
6
Clinical and genetic features of amyotrophic lateral sclerosis patients with mutations.患有突变的肌萎缩侧索硬化症患者的临床和遗传特征
Brain Commun. 2023 Mar 21;5(2):fcad087. doi: 10.1093/braincomms/fcad087. eCollection 2023.

本文引用的文献

1
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS.针对肌萎缩性侧索硬化症的反义寡核苷酸 Tofersen 的 1-2 期临床试验。
N Engl J Med. 2020 Jul 9;383(2):109-119. doi: 10.1056/NEJMoa2003715.
2
Prognostic factors in ALS: a comparison between Germany and China.肌萎缩侧索硬化症的预后因素：中德之间的比较。
J Neurol. 2019 Jun;266(6):1516-1525. doi: 10.1007/s00415-019-09290-4. Epub 2019 Mar 28.
3
Better survival in female -mutant patients with ALS: a study of -related natural history.肌萎缩侧索硬化症女性突变患者的更好生存率：一项相关自然史研究。
Transl Neurodegener. 2019 Jan 8;8:2. doi: 10.1186/s40035-018-0142-8. eCollection 2019.
4
Identification of an A4V SOD1 mutation in a Chinese patient with amyotrophic lateral sclerosis without the A4V founder effect common in North America.在一名无北美常见A4V奠基者效应的中国肌萎缩侧索硬化症患者中鉴定出A4V SOD1突变。
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):466-468. doi: 10.1080/21678421.2018.1451895. Epub 2018 Mar 22.
5
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.依达拉奉在明确诊断的肌萎缩侧索硬化症患者中的安全性和有效性：一项随机、双盲、安慰剂对照试验。
Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
6
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?肌萎缩侧索硬化症临床试验综述：二十年的失败。我们距离批准一种新疗法更近了吗？
Front Aging Neurosci. 2017 Mar 22;9:68. doi: 10.3389/fnagi.2017.00068. eCollection 2017.
7
Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis.肌萎缩侧索硬化症的遗传流行病学：系统评价和荟萃分析。
J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):540-549. doi: 10.1136/jnnp-2016-315018. Epub 2017 Jan 5.
8
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.定义超氧化物歧化酶1型肌萎缩侧索硬化症的自然史以指导治疗性临床试验设计。
J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):99-105. doi: 10.1136/jnnp-2016-313521. Epub 2016 Jun 3.
9
Natural history of young-adult amyotrophic lateral sclerosis.青年型肌萎缩侧索硬化症的自然病史。
Neurology. 2008 Sep 16;71(12):876-81. doi: 10.1212/01.wnl.0000312378.94737.45. Epub 2008 Jul 2.